Pembrolizumab for treatment of progressive multifocal leukoencephalopathy in primary immunodeficiency and/or hematologic malignancy: a case series of five patients

[1]  D. Galanaud,et al.  Immune checkpoint inhibitors for progressive multifocal leukoencephalopathy: a new gold standard? , 2021, Journal of Neurology.

[2]  D. Reich,et al.  Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease , 2020, Nature Reviews Neurology.

[3]  P. Rowlings,et al.  Progressive multifocal leukoencephalopathy associated with a lymphoproliferative disorder treated with pembrolizumab , 2020, Journal of NeuroVirology.

[4]  W. Schulz-Schaeffer,et al.  Clinical and magnetic resonance imaging monitoring in progressive multifocal leukoencephalopathy treated with pembrolizumab: a case report , 2020, Neurological Sciences.

[5]  A. Gass,et al.  Nivolumab for treatment of progressive multifocal leukoencephalopathy in Sézary syndrome , 2020, European journal of neurology.

[6]  G. Fink,et al.  Clearance of JC polyomavirus from cerebrospinal fluid following treatment with interleukin‐2 and pembrolizumab in an individual with progressive multifocal leukoencephalopathy and no underlying immune deficiency syndrome , 2020, European Journal of Neurology.

[7]  S. Henson,et al.  Sequential interleukin 2 and pembrolizumab use in progressive multifocal leukoencephalopathy , 2020, Neurology: Neuroimmunology & Neuroinflammation.

[8]  Ronak K. Kapadia,et al.  Stabilization of Progressive Multifocal Leukoencephalopathy After Pembrolizumab Treatment , 2020, The Neurohospitalist.

[9]  Marta Mozo Ruiz,et al.  Pembrolizumab treatment for progressive multifocal leukoencephalopathy in a patient with Human Immunodeficiency Virus infection. , 2020 .

[10]  M. T. D. Suso,et al.  Tratamiento con pembrolizumab en paciente con infección por virus de la inmunodeficiencia humana y leucoencefalopatía multifocal progresiva , 2020 .

[11]  S. Demeret,et al.  Postallogeneic transplantation progressive multifocal leukoencephalopathy successfully treated by nivolumab , 2019, British journal of haematology.

[12]  R. D. Pasquier.  Pembrolizumab as a treatment for PML? Waiting for Godot. , 2019 .

[13]  C. Mengelle,et al.  Effectiveness of Immune Checkpoint Inhibitors in Transplant Recipients with Progressive Multifocal Leukoencephalopathy , 2019, Emerging infectious diseases.

[14]  A. Straube,et al.  Pembrolizumab for progressive multifocal leukoencephalopathy due to primary immunodeficiency , 2019, Neurology: Neuroimmunology & Neuroinflammation.

[15]  H. Wiendl,et al.  Ineffective treatment of PML with pembrolizumab , 2019, Neurology: Neuroimmunology & Neuroinflammation.

[16]  F. Chapon,et al.  Sustained Response and Rationale of Programmed Cell Death-1-Targeting for Progressive Multifocal Leukoencephalopathy , 2019, Open forum infectious diseases.

[17]  C. Weiller,et al.  Treatment of Progressive Multifocal Leukoencephalopathy with Pembrolizumab. , 2019, The New England journal of medicine.

[18]  Bryan R. Smith,et al.  Pembrolizumab Treatment for Progressive Multifocal Leukoencephalopathy , 2019, The New England journal of medicine.

[19]  C. Mengelle,et al.  Treatment of Progressive Multifocal Leukoencephalopathy with Nivolumab. , 2019, The New England journal of medicine.

[20]  D. Clifford,et al.  Progressive multifocal leukoencephalopathy treated with nivolumab , 2019, Journal of NeuroVirology.

[21]  A. Verma,et al.  Characteristics and outcomes of progressive multifocal leukoencephalopathy in hematologic malignancies and stem cell transplant – a case series , 2018, Leukemia & lymphoma.

[22]  S. Lewin,et al.  Programmed cell death-1 contributes to the establishment and maintenance of HIV-1 latency , 2018, AIDS.

[23]  C. Quereda,et al.  Incidence and prognosis of immune reconstitution inflammatory syndrome in HIV‐associated progressive multifocal leucoencephalopathy , 2016, European journal of neurology.

[24]  W. Curry,et al.  Immunomodulation: checkpoint blockade etc. , 2015, Neuro-oncology.

[25]  E. Bord,et al.  Increased Program Cell Death–1 Expression on T Lymphocytes of Patients With Progressive Multifocal Leukoencephalopathy , 2012, Journal of acquired immune deficiency syndromes.

[26]  M. van der Burg,et al.  Age‐matched Reference Values for B‐lymphocyte Subpopulations and CVID Classifications in Children , 2011, Scandinavian journal of immunology.

[27]  D. Costagliola,et al.  Improved Survival of HIV-1-Infected Patients with Progressive Multifocal Leukoencephalopathy Receiving Early 5-Drug Combination Antiretroviral Therapy , 2011, PloS one.

[28]  A. Rieger,et al.  Identification of PD-1 as a Unique Marker for Failing Immune Reconstitution in HIV-1–Infected Patients on Treatment , 2011, Journal of acquired immune deficiency syndromes.

[29]  G. Freeman,et al.  Enhancing SIV-Specific Immunity In Vivo by PD-1 Blockade , 2008, Nature.

[30]  G. Gao,et al.  PD-1 up-regulation is correlated with HIV-specific memory CD8+ T-cell exhaustion in typical progressors but not in long-term nonprogressors. , 2007, Blood.

[31]  G. Freeman,et al.  Restoring function in exhausted CD8 T cells during chronic viral infection , 2006, Nature.

[32]  R. Levy,et al.  Predictive factors for prolonged survival in acquired immunodeficiency syndrome—associated progressive multifocal leukoencephalopathy , 1998, Annals of neurology.

[33]  T. Reichert,et al.  Age-related changes in human blood lymphocyte subpopulations. II. Varying kinetics of percentage and absolute count measurements. , 1994, Clinical immunology and immunopathology.